Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

741. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. 17673732 2007 08 24 2007 09 04 2014 09 04 1756-1833 335 7616 2007 Aug 25 BMJ (Clinical research ed.) BMJ Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. 383 To assess whether screening improves the detection of atrial fibrillation (cluster randomisation) and to compare (...) and invitation for electrocardiography if the pulse was irregular). Screening took place over 12 months in each practice from October 2001 to February 2003. No active screening took place in control practices. Newly identified atrial fibrillation. The detection rate of new cases of atrial fibrillation was 1.63% a year in the intervention practices and 1.04% in control practices (difference 0.59%, 95% confidence interval 0.20% to 0.98%). Systematic and opportunistic screening detected similar numbers of new

BMJ2007 Full Text: Link to full Text with Trip Pro

742. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. 17693178 2007 08 13 2007 08 21 2016 11 22 1474-547X 370 9586 2007 Aug 11 Lancet (London, England) Lancet Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA (...) ): a randomised controlled trial. 493-503 Anticoagulants are more effective than antiplatelet agents at reducing stroke risk in patients with atrial fibrillation, but whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown. We assessed whether warfarin reduced risk of major stroke, arterial embolism, or other intracranial haemorrhage compared with aspirin in elderly patients. 973 patients aged 75 years or over (mean age 81.5 years, SD 4.2) with atrial fibrillation were

Lancet2007

743. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease.

Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. 17804844 2007 09 06 2007 09 10 2010 11 18 1533-4406 357 10 2007 Sep 06 The New England journal of medicine N. Engl. J. Med. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. 1000-8 Conventional dual-chamber pacing maintains atrioventricular synchrony but results in high percentages of ventricular pacing, which causes ventricular desynchronization and has been linked (...) to an increased risk of atrial fibrillation in patients with sinus-node disease. We randomly assigned 1065 patients with sinus-node disease, intact atrioventricular conduction, and a normal QRS interval to receive conventional dual-chamber pacing (535 patients) or dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization (530 patients). The primary end point was time

NEJM2007

744. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. 17804843 2007 09 06 2007 09 10 2014 11 20 1533-4406 357 10 2007 Sep 06 The New England journal of medicine N. Engl. J. Med. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. 987-99 Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects. Dronedarone is a new antiarrhythmic agent pharmacologically related (...) was monitored transtelephonically on days 2, 3, and 5; at 3, 5, 7, and 10 months; during recurrence of arrhythmia; and at nine scheduled visits during a 12-month period. The primary end point was the time to the first recurrence of atrial fibrillation or flutter. In the European trial, the median times to the recurrence of arrhythmia were 41 days in the placebo group and 96 days in the dronedarone group (P=0.01). The corresponding durations in the non-European trial were 59 and 158 days (P=0.002

NEJM2007

745. ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response

ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Article Text Therapeutics ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2006

746. Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation

Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation Article Text Therapeutics Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular

Evidence-Based Medicine (Requires free registration)2006

747. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation.

Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. BACKGROUND: Atrial fibrillation is the most common type of cardiac arrhythmia and a leading cause of cardiovascular morbidity, particularly stroke. The cardiac gap-junction protein connexin 40 is expressed selectively in atrial myocytes and mediates the coordinated electrical activation of the atria. We hypothesized that idiopathic atrial fibrillation has a genetic basis and that tissue-specific mutations in GJA5, the gene (...) encoding connexin 40, may predispose the atria to fibrillation. METHODS: We sequenced GJA5 from genomic DNA isolated from resected cardiac tissue and peripheral lymphocytes from 15 patients with idiopathic atrial fibrillation. Identified GJA5 mutations were transfected into a gap-junction-deficient cell line to assess their functional effects on protein transport and intercellular electrical coupling. RESULTS: Four novel heterozygous missense mutations were identified in 4 of the 15 patients. In three

NEJM2006

748. Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation

Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Article Text Treatment Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Free Gina

Evidence-Based Nursing (Requires free registration)2006

749. Rate control was more cost effective than rhythm control in persistent atrial fibrillation

Rate control was more cost effective than rhythm control in persistent atrial fibrillation Rate control was more cost effective than rhythm control in persistent atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rate control was more cost effective than rhythm control in persistent atrial fibrillation Article Text Economics Rate control was more cost effective than rhythm control in persistent atrial fibrillation Free David Newman , MD Statistics from Altmetric.com No Altmetric data available for this article. Hagens VE, Vermeulen

Evidence-Based Medicine (Requires free registration)2006

750. Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation

Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation Article Text Aetiology Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation Free Apoor S Gami , MD Statistics from Altmetric.com No Altmetric data available for this article. Shireman TI

Evidence-Based Medicine (Requires free registration)2006

751. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. OBJECTIVES: To quantify the influence of physicians' experiences of adverse events in patients with atrial fibrillation who were taking warfarin. DESIGN: Population based, matched pair before and after analysis. SETTING: Database study in Ontario, Canada. PARTICIPANTS: The physicians of patients with atrial fibrillation admitted to hospital for adverse events (major haemorrhage while (...) taking warfarin and thromboembolic strokes while not taking warfarin). Pairs of other patients with atrial fibrillation treated by the same physicians were selected. MAIN OUTCOME MEASURES: Odds of receiving warfarin by matched pairs of a given physician's patients (one treated after and one treated before the event) were compared, with adjustment for stroke and bleeding risk factors that might also influence warfarin use. The odds of prescriptions for angiotensin converting enzyme (ACE

BMJ2006 Full Text: Link to full Text with Trip Pro

752. Controversies in atrial fibrillation.

Controversies in atrial fibrillation. Atrial fibrillation is the most common sustained cardiac arrhythmia, and contributes greatly to cardiovascular morbidity and mortality. Many aspects of the management of atrial fibrillation remain controversial. We address nine specific controversies in atrial fibrillation management, briefly focusing on the relations between mechanisms and therapy, the roles of rhythm and rate control, the definition of optimum rate control, the need for early

Lancet2006

753. Is pulse palpation helpful in detecting atrial fibrillation: a systematic review

Is pulse palpation helpful in detecting atrial fibrillation: a systematic review Is pulse palpation helpful in detecting atrial fibrillation: a systematic review Is pulse palpation helpful in detecting atrial fibrillation: a systematic review Cooke G, Doust J, Sanders S CRD summary This well-conducted review reliably concluded that pulse palpation can be useful for ruling out atrial fibrillation. Authors' objectives To determine the accuracy of pulse palpation to detect atrial fibrillation (AF (...) : 84, 97) and the pooled specificity 72% (95% CI: 69, 75). Positive LRs ranged from 3.1 to 4.1 and negative LRs from 0.024 to 0.12. The pooled positive LR was 3.4 (95% CI: 3.2, 3.7) and the pooled negative LR 0.11 (95% CI: 0.06, 0.20). The chi-squared test for heterogeneity was 3.87 (P=0.14) for the positive LR and 1.49 (P=0.49) for the negative LR, indicating the consistency of results between studies. Authors' conclusions Pulse palpation can be used to rule out AF as it has a high sensitivity

DARE.2006

754. The impact of suppressing the renin-angiotensin system on atrial fibrillation

The impact of suppressing the renin-angiotensin system on atrial fibrillation The impact of suppressing the renin-angiotensin system on atrial fibrillation The impact of suppressing the renin-angiotensin system on atrial fibrillation Kalus J S, Coleman C I, White C M CRD summary The authors concluded that angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers prevent the development of new-onset atrial fibrillation (AF), improve the likelihood of successful direct current (...) cardioversion (DCC), and prevent recurrence of AF after DCC. Given the methodological limitations and the unknown quality of the included studies, the results should be interpreted with caution. Authors' objectives To evaluate the impact of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) on the occurrence of new-onset atrial fibrillation (AF), rate of successful direct current cardioversion (DCC) of AF, and rate of AF recurrence. Searching MEDLINE, EMBASE and CINAHL

DARE.2006

755. Quality of life in patients with atrial fibrillation: a systematic review

Quality of life in patients with atrial fibrillation: a systematic review Quality of life in patients with atrial fibrillation: a systematic review Quality of life in patients with atrial fibrillation: a systematic review Thrall G, Lane D, Carroll D, Lip G Y CRD summary This review concluded that quality of life in patients with atrial fibrillation can be significantly improved by both rate and rhythm control strategies. The generalisability of many of the included studies is uncertain (...) but, overall, the authors' conclusions are in line with the evidence presented and appear reliable. Authors' objectives To assess the effects of rate control and rhythm control interventions on quality of life (QoL) in patients with atrial fibrillation (AF). The review also compared the QoL of patients with AF with that of healthy controls, the general population and patients with other cardiac diseases. This aspect of the review is not covered in this abstract. Searching MEDLINE, EMBASE, PsycINFO

DARE.2006

756. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis

Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis Bagshaw S M, Galbraith P D, Mitchell L B, Sauve R, Exner D V, Ghali W A CRD summary This review evaluated the effects of amiodarone in post-operative atrial fibrillation. It concluded (...) that amiodarone prophylaxis is associated with a significant reduction in atrial fibrillation after cardiac surgery, as well as a reduction in peri-operative ventricular tachyarrhythmias and strokes and a short but significant reduction in hospital stay. The authors' conclusions reflect the evidence presented and are likely to be reliable. Authors' objectives To evaluate the effect of amiodarone in post-operative atrial fibrillation (AF). Searching MEDLINE, EMBASE and the Cochrane Controlled Trials Register

DARE.2006

757. Percutaneous radiofrequency ablation for atrial fibrillation

Percutaneous radiofrequency ablation for atrial fibrillation Percutaneous radiofrequency ablation for atrial fibrillation Percutaneous radiofrequency ablation for atrial fibrillation National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Percutaneous (...) radiofrequency ablation for atrial fibrillation. London: National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance 168. 2006 Authors' objectives This study aims to assess the current evidence on percutaneous radiofrequency ablation for atrial fibrillation. Authors' conclusions 1 Guidance 1.1 Current evidence on the safety and efficacy of percutaneous radiofrequency ablation for atrial fibrillation appears adequate to support the use of this procedure in appropriately

Health Technology Assessment (HTA) Database.2006

758. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation

Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Chan P S, Vijan S, Morady F, Oral H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of left atrial catheter ablation (LACA) in the treatment of atrial fibrillation (AF). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population Three hypothetical study populations were considered in the analysis. These were 65-year-old patients at low risk of stroke, 65-year-old patients at moderate risk of stroke, and 55-year-old patients at low

NHS Economic Evaluation Database.2006

759. Ablation for atrial fibrillation: an evidence-based analysis

Ablation for atrial fibrillation: an evidence-based analysis Ablation for atrial fibrillation: an evidence-based analysis Ablation for atrial fibrillation: an evidence-based analysis Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ablation for atrial fibrillation: an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS (...) ). Volume 6(7). 2006 Authors' objectives At the request of the Ontario Health Technology Assessment Committee, the Medical Advisory Secretariat systematically reviewed the evidence of the effectiveness, safety, and costing of ablation methods to manage atrial fibrillation (AF). The ablation methods reviewed were catheter ablation and surgical ablation. Authors' conclusions Catheter ablation appears to be an effective treatment for patients with drug-refractory AF whose treatment alternatives are limited

Health Technology Assessment (HTA) Database.2006

760. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery

High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery. London: National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance 184. 2006 Authors' objectives This study aims to assess the current evidence on high-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery. Authors' conclusions

Health Technology Assessment (HTA) Database.2006